Reséndiz-Aparicio JC, Padilla-Huicab JM, Martínez-Juárez IE, Hernández-Martínez G, López-Correa E, Vázquez-Juárez B, Huerta-Albarrán R, Rivera-Acuña C

Language: English
References: 52
Page: 89-96
PDF size: 172.62 Kb.

ABSTRACT

Approximately 65% of children with newly diagnosed epilepsy achieve sustained control of their epileptic seizures with the antiepileptic drug (AED) initially prescribed, and 15-20% require the combination of other AEDs. To begin treatment with an AED, basic aspects should be considered, such as the capacity for absorption, distribution, metabolism, and elimination of each AED. Treatment with an AED in pediatric patients, as for any age, must be personalized, but in these cases, the biological age and its degree of development are fundamental. Furthermore, the type of seizure, type of epileptic syndrome, comorbidity, in many cases the etiology, and even other aspects such as tolerability and availability of use must be considered. If adequate seizure control is not achieved, synergistic combinations could be used, making sure that adverse effects are not increased. Remember that a high percentage of patients initiate their epilepsy in the pediatric stage, which is why management in this age group is fundamental, and doses must always be calculated in relation to the weight of the patient.

REFERENCES

1. Donovan MD, Griffin BT, Kharoshankaya L, Cryan JF, Boylan GB. Pharmacotherapy for neonatal seizures: current knowledge and future perspectives. Drugs. 2016;76:647-61.

2. Sankaraneni R, Lachhwani D. Antiepileptic drugs a review. Pediatr Ann. 2015;44:e36-42.

3. Pellock JM, Arzimanoglou A, D’Cruz O, et al. Extrapolating evidence of antiepileptic drug efficacy in adults to children ≥2 years of age with focal seizures: the case for disease similarity. Epilepsia. 2017;58:1686-96.

4. Yozawitz E, Stacey A, Pressler RM. Pharmacotherapy for seizures in neonates with hypoxic ischemic encephalopathy. Paediatr Drugs. 2017; 19:553-67.

5. Linder C, Wide K, Walander M, et al. Comparison between dried blood spot and plasma sampling for therapeutic drug monitoring of antiepileptic drugs in children with epilepsy: a step towards home sampling. Clin Biochem. 2017;50:418-24.

6. Landmark CJ, Johannessen SI, Tomson T. Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring. Epileptic Disord. 2016; 18:367-83.

7. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475-82.

8. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58:512-21.

9. Shellhaas RA, Wusthoff CJ, Tsuchida TN, et al. Profile of neonatal epilepsies: characteristics of a prospective US cohort. Neurology. 2017; 89:893-9.

10. Sands TT, Balestri M, Bellini G, et al. Rapid and safe response to low-dose carbamazepine in neonatal epilepsy. Epilepsia. 2016;57:2019-30.

11. Yamamoto H, Okumura A, Fukuda M. Epilepsies and epileptic syndromes starting in the neonatal period. Brain Dev. 2011;33:213-20.

12. Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the guideline development subcommittee of the American academy of neurology and the practice committee of the child neurology society. Neurology. 2012; 78:1974-80.

13. Hancock EC, Osborne JP, Edwards SW. Treatment of Infantile Spasms. Copyright © 2014 the Cochrane Collaboration. Hoboken: Publicado Por John Wiley and Sons, Ltd.; 2014.

14. Tournay AE. DynaMed Plus: patients with Lennox-Gastaut Síndrome. Spain: Marzo; 2018.

15. Epilepsies: Diagnosis and Management. Clinical Guideline Publicada: 11 Enero; 2012. http://www.nice.org.uk/guidance/cg137.

16. Lemmon ME, Kossoff EH. New treatment options for lennox-gastaut syndrome. Curr Treat Options Neurol. 2013;15:519-28.

17. Hancock EC, Cross H. Treatment of Lennox-Gastaut syndrome. Copyright © 2013 the Cochrane Collaboration. Hoboken: Publicado Por John Wiley and Sons, Ltd.; 2013.

18. Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the lennox-gastaut syndrome. Lamictal lennox- gastaut study group. N Engl J Med. 1997;337:1807-12.

19. Kossoff EH, Shields WD. Nonpharmacologic care for patients with lennox- gastaut syndrome: ketogenic diets and vagus nerve stimulation. Epilepsia. 2014;55 Suppl 4:29-33.

20. Lancman G, Virk M, Shao H, et al. Vagus nerve stimulation vs. Corpus callosotomy in the treatment of lennox-gastaut syndrome: a meta-analysis. Seizure. 2013;22:3-8.

21. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with lennox-gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018; 391:1085-96.

22. Tzadok M, Uliel-Siboni S, Linder I, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: the current israeli experience. Seizure. 2016;35:41-4.

23. Kilaru S, Bergqvist AG. Current treatment of myoclonic astatic epilepsy: clinical experience at the children’s hospital of Philadelphia. Epilepsia. 2007;48:1703-7.

24. Kelley SA, Kossoff EH. Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress. Dev Med Child Neurol. 2010;52:988-93.

25. von Stülpnagel C, Coppola G, Striano P, et al. First long-term experience with the orphan drug rufinamide in children with myoclonic-astatic epilepsy (Doose syndrome). Eur J Paediatr Neurol. 2012;16:459-63.

26. Mizrahi EM, Watanabe K, Symptomatic neonatal seizures. In: Roger J, Bureau M, Dravet CH, editors Epileptic Syndromes in Infancy, Childhood and Adolescencie. 3rd ed. London: John Libbey; 2002.

27. Weir E, Gibbs J, Appleton R. Panayiotopoulos syndrome and benign partial epilepsy with centro-temporal spikes: a comparative incidence study. Seizure. 2018;57:66-9.

28. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094-120.

29. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54:551-63.

30. Wilmshurst JM, Gaillard WD, Vinayan KP, et al. Summary of recommendations for the management of infantile seizures: task force report for the ILAE commission of pediatrics. Epilepsia. 2015;56:1185-97.

31. Arya R, Giridharan N, Anand V, Garg SK. Clobazam monotherapy for focal or generalized seizures. Cochrane Database Syst Rev. 2018; 7:CD009258.

32. Nevitt SJ, Marson AG, Weston J, Smith CT. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2017;2:CD001911.

33. Nevitt SJ, Smith CT, Weston J, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2018;6:CD001031.

34. Aneja S, Sharma S. Newer anti-epileptic drugs. Indian Pediatr. 2013; 50:1033-40.

35. Sánchez-Álvarez JC, Ramos-Lizana J, Machado-Casas IS, et al. Combined treatment with antiepileptic drugs. Andalusian epilepsy guide 2015. Rev Neurol. 2015;60:365-79.

36. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000-15.

37. Smith CT, Marson AG, Chadwick DW, Williamson PR. Multiple treatment comparisons in epilepsy monotherapy trials. Trials. 2007;8:34.

38. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402-8.

39. Wechsler RT, Li G, French J, et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. Epilepsia. 2014;55:1088-98.

40. Lang N, Lange M, Schmitt FC, et al. Intravenous lacosamide in clinical practice-results from an independent registry. Seizure. 2016;39:5-9.

41. Maguire M, Marson AG, Ramaratnam S. Epilepsy (partial). BMJ Clin Evid. 2011;2011:1214.

42. Smith CT, Marson AG, Williamson PR. Carbamazepine versus phenobarbitone monotherapy for epilepsy. Cochrane Database Syst Rev. 2003; 1:CD001904.

43. Nolan SJ, Smith CT, Pulman J, Marson AG. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database Syst Rev. 2013;1:CD002217.

44. Nolan SJ, Marson AG, Pulman J, Smith CT. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database Syst Rev. 2013;8:CD001769.

45. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. 2003;107:165-75.

46. Gamble CL, Williamson PR, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev. 2006; 1:CD001031.

47. Arya R, Glauser TA. Pharmacotherapy of focal epilepsy in children: a systematic review of approved agents. CNS Drugs. 2013;27:273-86.

48. Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009; 4:CD006453.

49. Perry S, Holt P, Benatar M. Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of age. J Child Neurol. 2008;23:515-9.

50. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian study group for childhood epilepsy. Epilepsia. 1998;39:952-9.

51. Bawden HN, Camfield CS, Camfield PR, et al. The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian study group for childhood epilepsy. Epilepsy Res. 1999; 33:133-43.

52. Rosenow F, Schade-Brittinger C, Burchardi N, et al. The laLiMo trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy an open-label, prospective, randomised controlled multicenter study. J Neurol Neurosurg Psychiatry. 2012;83:1093-8.